Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide Plus Zoledronic Acid vs Zoledronic Acid Alone in Early Stage Multiple Myeloma
NCT00432458Phase 3Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2003
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of thalidomide in multiple myeloma (MM) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Time to Disease Progression at 5 years. Started Jul 2003; status: completed.
02
Drugs
thalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00432458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00432458.